Theory and practice of supersaturatable formulations for poorly soluble drugs

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv. Drug Deliv. Rev. 64(6), 480–495 (2012).
  Medline CASGoogle Scholar
• 2 Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21(2), 201–230 (2004).
  Medline CASGoogle Scholar
• 3 Kawakami K, Miyoshi K, Ida Y. Solubilization behavior of poorly soluble drugs with combined use of gelucire 44/14 and cosolvent. J. Pharm. Sci. 93(6), 1471–1479 (2004).
  Medline CASGoogle Scholar
• 4 Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 28(1–2), 7–14 (2006).• Valuable example which showed that addition of organic solvent significantly decreased solubilization capacity of micelles.
  Medline CASGoogle Scholar
• 5 Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 52(8), 900–915 (2004).
  Medline CASGoogle Scholar
• 6 Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59(7), 645–666 (2007).
  Medline CASGoogle Scholar
• 7 Yang G, Jain N, Yalkowsky SH. Combined effect of SLS and (SBE)7M-beta-CD on the solubilization of NSC-639829. Int. J. Pharm. 269(1), 141–148 (2004).
  Medline CASGoogle Scholar
• 8 Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. Thermodynamic analysis. J. Pharm. Sci. 99(3), 1254–1264 (2010).•• Theoretical approach to predict solubility advantage of amorphous solids compared with crystalline solids. Comparison with experimental data was also provided.
  Medline CASGoogle Scholar
• 9 Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98(8), 2549–2572 (2009).
  Medline CASGoogle Scholar
• 10 Verreck G, Vandecruys R, De Conde V et al. The use of three different solid dispersion formulations – melt extrusion, film-coated beads, and a glass thermoplastic system – to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J. Pharm. Sci. 93(5), 1217–1228 (2004).• Precious report that showed dissolution rate did not function in the prediction of oral absorption in humans.
  Medline CASGoogle Scholar
• 11 Zhang S, Kawakami K, Yamamoto M et al. Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug. Mol. Pharm. 8(3), 807–813 (2011).
  MedlineGoogle Scholar
• 12 Mah PT, Laaksonen T, Rades T et al. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide. Mol. Pharm. 11(1), 234–242 (2014).
  Medline CASGoogle Scholar
• 13 Alonzo DE, Gao Y, Zhou D et al. Dissolution and precipitation behavior of amorphous solid dispersions. J. Pharm. Sci. 100(8), 3316–3331 (2011).• Pioneering work that proved formation of nanoparticles during dissolution of amorphous solid dispersions.
  Medline CASGoogle Scholar
• 14 Higashi K, Yamamoto K, Pandey MK et al. Insights into atomic-level interaction between mefenamic acid and Eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy. Mol. Pharm. 11(1), 351–357 (2014).
  Medline CASGoogle Scholar
• 15 Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int. J. Pharm. 352(1–2), 309–316 (2008).
  Medline CASGoogle Scholar
• 16 Ueda K, Higashi K, Yamamoto K, Moribe K. The effect of HPMCAS functional groups on drug crystallization from the supersaturated state and dissolution improvement. Int. J. Pharm. 464(1–2), 205–213 (2014).
  Medline CASGoogle Scholar
• 17 Yin L, Hillmyer MA. Preparation and performance of hydroxypropyl methylcellulose esters of substituted succinates for in vitro supersaturation of a crystalline hydrophobic drug. Mol. Pharm. 11(1), 175–185 (2014).
  Medline CASGoogle Scholar
• 18 Kawakami K, Harada T, Miura K et al. Relationship between crystallization tendencies during cooling from melt and isothermal storage: toward a general understanding of physical stability of pharmaceutical glasses. Mol. Pharm. 11(6), 1835–1843 (2014).•• General rule for estimating crystallization time of low-molecular-weight pharmaceutical compounds was presented, although it has been understood on case-by-case basis.
  Medline CASGoogle Scholar
• 19 Kawakami K. Surface effects on the crystallization of ritonavir glass. J. Pharm. Sci. 104(1), 276–279 (2015).
  Medline CASGoogle Scholar
• 20 Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage – impact of different polymers. J. Pharm. Sci. 102(1), 171–184 (2013).
  Medline CASGoogle Scholar
• 21 Janssens S, De Zeure A, Paudel A et al. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and Eudragit E100. Pharm. Res. 27(5), 775–785 (2010).
  Medline CASGoogle Scholar
• 22 Guns S, Dereymaker A, Kayaert P et al. Comparison between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm. Res. 28(3), 673–682 (2011).
  Medline CASGoogle Scholar
• 23 Bank M, Leffingwell J, Thies C. The influence of solvent upon the compatibility of polystyrene and poly(vinyl methyl ether). Macromolecules 4(1), 43–46 (1971).
  CASGoogle Scholar
• 24 Kawakami K, Hasegawa Y, Deguchi K et al. Competition of thermodynamic and dynamic factors during formation of multi-component particles via spray-drying. J. Pharm. Sci. 102(2), 518–529 (2013).
  Medline CASGoogle Scholar
• 25 Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with Neusilin. J. Pharm. Sci. 92(3), 536–551 (2003).
  Medline CASGoogle Scholar
• 26 Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int. J. Pharm. 453(1), 181–197 (2013).
  Medline CASGoogle Scholar
• 27 Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 91(2), 492–507 (2002).
  Medline CASGoogle Scholar
• 28 Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88(10), 1058–1066 (1999).
  Medline CASGoogle Scholar
• 29 Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J. Pharm. Sci. 99(2), 587–597 (2010).
  Medline CASGoogle Scholar
• 30 Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54(2), 107–117 (2002).
  Medline CASGoogle Scholar
• 31 Repka MA, Shah S, Lu J et al. Melt extrusion: process to product. Exp. Opin. Drug Deliv. 9(1), 105–125 (2012).
  Medline CASGoogle Scholar
• 32 Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur. J. Pharm. Sci. 15(2), 115–133 (2002).
  Medline CASGoogle Scholar
• 33 Yasuji T, Takeuchi H, Kawashima Y. Particle design of poorly water-soluble substances using supercritical fluid technologies. Adv. Drug Deliv. Rev. 60(3), 388–398 (2008).
  Medline CASGoogle Scholar
• 34 Rumondor ACF, Marsac RJ, Stanford LA, Taylor LS. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol. Pharm. 6(5), 1492–1505 (2009).
  Medline CASGoogle Scholar
• 35 Marsac RJ, Rumondor ACF, Nivens DE et al. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J. Pharm. Sci. 99(1), 169–185 (2010).
  Medline CASGoogle Scholar
• 36 Hancock BC, Zografi G. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res. 11(4), 471–477 (1994).
  Medline CASGoogle Scholar
• 37 Dong Z, Chatterji A, Sandhu H et al. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int. J. Pharm. 355(1–2), 141–149 (2008).
  Medline CASGoogle Scholar
• 38 Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9(11), 866–872 (1961).
  CASGoogle Scholar
• 39 Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18(2), 113–120 (2003).
  Medline CASGoogle Scholar
• 40 Van Eedenbrugh B, Van den Mooter G, Augustijins P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364(1), 64–75 (2008).
  MedlineGoogle Scholar
• 41 Kesisoglou F, Panmai S, Wu Y. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59(7), 631–644 (2007).
  Medline CASGoogle Scholar
• 42 Heng JYY, Thielmann F, Williams DR. The effects of milling on the surface properties of form I paracetamol crystals. Pharm. Res. 23(8), 1918–1927 (2006).
  Medline CASGoogle Scholar
• 43 Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13(12), 1838–1845 (1996).
  Medline CASGoogle Scholar
• 44 Lai SK, O'Hanlon DE, Harrold S et al. Rapid Transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA 104(5), 1482–1487 (2007).
  Medline CASGoogle Scholar
• 45 Wanawongthai C, Pongpeerapat A, Higashi K et al. 2009. Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixture. Int. J. Pharm. 376(1–2), 169–175 (2009).
  Medline CASGoogle Scholar
• 46 Rasenack N, Hartenhauer H, Müller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 254(2), 137–145 (2003).
  Medline CASGoogle Scholar
• 47 De Waard H, Hinrichs WLJ, Frijlink HW. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Control. Release 128(2), 179–183 (2008).
  Medline CASGoogle Scholar
• 48 Lee J, Choi, JY, Park CH. Characteristics of polymers enabling nano-comminution of water-insoluble drugs. Int. J. Pharm. 355(1–2), 328–336 (2008).
  Medline CASGoogle Scholar
• 49 George M, Ghosh I. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur. J. Pharm. Sci. 48(1–2), 142–152 (2013).
  Medline CASGoogle Scholar
• 50 Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 58(15), 1688–1713 (2006).
  Medline CASGoogle Scholar
• 51 Kawakami K, Nishihara Y, Hirano K. Effect of hydrophilic polymers on physical stability of liposome dispersions. J. Phys. Chem. B 105(12), 2374–2385 (2001).
  CASGoogle Scholar
• 52 Wu Y, Loper A, Landis E et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285(1–2), 135–146 (2004).
  Medline CASGoogle Scholar
• 53 Brough C, Williams III, RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int. J. Pharm. 453(1), 157–166 (2013).
  Medline CASGoogle Scholar
• 54 Li W, Quan P, Zhang Y et al. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Int. J. Pharm. 460(1–2), 13–23 (2014).
  Medline CASGoogle Scholar
• 55 Kawakami K, Yoshikawa T, Moroto Y et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. J. Control. Release 81(1–2), 65–74 (2002).
  Medline CASGoogle Scholar
• 56 Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1–2), 89–121 (2000).
  Medline CASGoogle Scholar
• 57 Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv. Drug Deliv. Rev. 60(6), 638–656 (2008).
  Medline CASGoogle Scholar
• 58 Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83(3), 444–446 (1994).
  Medline CASGoogle Scholar
• 59 Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60(6), 673–691 (2008).• Well-summarized review that enables overview of researches on self-(micro)emulsifying drug-delivery systems.
  Medline CASGoogle Scholar
• 60 Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 21(8), 1405–1412 (2004).
  Medline CASGoogle Scholar
• 61 Cuine JF, McEvoy CL, Charman WN et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 97(2), 995–1012 (2008).
  Medline CASGoogle Scholar
• 62 Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J. Control. Release 81(1–2), 75–82 (2002).
  Medline CASGoogle Scholar
• 63 Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res. 21(2), 261–270 (2004).
  Medline CASGoogle Scholar
• 64 Gao P, Rush BD, Pfund WP et al. Development of a supersaturatable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92(12), 2386–2398 (2003).
  Medline CASGoogle Scholar
• 65 Kawakami K. Current status of amorphous formulation and other supersaturatable dosage forms as formulations for early clinical phases. J. Pharm. Sci. 98(9), 2875–2885 (2009).
  Medline CASGoogle Scholar